Overview
AbCellera Q3 2025 revenue rises to $9 mln, beating analyst expectations
Net loss widens to $57.1 mln, driven by higher R&D expenses
Company advances two lead programs through Phase 1 clinical trials
Result Drivers
R&D INVESTMENTS - Increased R&D expenses focused on internal programs, including $15 mln investment in two lead programs
LIQUIDITY MANAGEMENT - Maintained $680 mln in available liquidity to support strategic execution
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$9 mln
$5.91 mln (8 Analysts)
Q3 Net Income
-$57.10 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Abcellera Biologics Inc is $8.50, about 44.8% above its November 5 closing price of $4.69
Press Release: ID:nBw6KWm87a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)